Interim Estimates Reported for 2025-26 Seasonal Influenza Vaccine Effectiveness in US Population

An interim observational report provides early estimates of vaccine effectiveness for the 2025-26 seasonal influenza vaccine in the United States population. The analysis covers the period from September 2025 through February 2026. The report does not specify a comparator group, sample size, or the exact methodology used for this interim assessment.

The main finding is that interim vaccine effectiveness estimates have been reported, but no specific numerical effect sizes, absolute numbers, confidence intervals, or p-values are provided. The direction of the effect (whether the vaccine showed positive or negative effectiveness) is also not reported. No safety, tolerability, or adverse event data are included in this interim report.

Key limitations include the observational nature of the data, which means findings show association rather than causation. As an interim report, these are not final results and should not be used to draw definitive conclusions about the vaccine's performance. The absence of reported effect sizes, confidence intervals, and safety information significantly limits clinical interpretation.

For practice, clinicians should recognize this as a very preliminary signal that requires confirmation with complete, peer-reviewed data. The report does not provide sufficient information to guide clinical decisions about the 2025-26 influenza vaccine at this time. Final effectiveness and safety assessments will be needed once the full season data are analyzed and published.